THE ROLE OF INSULIN-LIKE GROWTH FACTOR-1 AND INSULIN IN DEVELOPMENT OF COLORECTAL CANCER.

The study's goal is to discover the function of the IGF-1 factor and insulin in the development of colorectal cancer. Changes in these factors should be explored at various phases of colorectal cancer, including the preoperative and postoperative periods. 38 patients were selected for the study. Patients were divided into two groups: the first group - patients with colorectal cancer, and the second group - practically healthy. The first group included 27 patients with colorectal cancer. The second group included 11 practically healthy patients, who ranged in age from 45 to 65. The patients underwent physical and clinical-laboratory examinations: IGF-1 laboratory test: determination of IGF binding-protein 3 and Insulin levels. The study showed that the levels of IGF-1 and insulin increased significantly in patients with colorectal cancer, while the level of IGF binding-protein 3 decreased sharply. The difference between preoperative and postoperative biomarkers was negligible. According to our findings, an increase in insulin and IGF-1 levels, as well as a substantial reduction in IGF binding-protein 3 levels, may play a role in the development of colorectal cancer, although their alterations do not vary significantly in the first three phases of disease progression. It should be noted that these indices decreased in the fourth stage.

ACTION OF SIMVASTATIN IN IMPROVING COGNITIVE FUNCTIONS IN VASCULAR DEMENTIA.

The purpose of this study was to determine the efficacy and safety of statins in improving cognitive function in patients with vascular dementia. As the most important etiological factors of the disease are atherosclerotic vascular lesions, one of the important areas of treatment is lipid metabolism analysis and drug treatment for dyslipidemia. 31 patients were selected for the study, ages 65-65 years, 18 males, 13 females. Twenty patients were included in the study group, treated with Simvastatin (80 mg daily dose). 11 patients were included in the control group. They received placebo therapy. Patients were examined every 4 weeks for 12 weeks using a neuropsychological test with mini-mental scaling, and both groups had low-density lipoprotein and cholesterol levels before and after treatment. In the 12-week post-treatment group, low-density lipoprotein levels were reduced by 54% and cholesterol by 48%. Neuropsychological status examination revealed deterioration of cognitive functions and no difference was observed between study and control group data. Based on the data obtained from our study, it should be noted that correction of lipid metabolism by statins in patients with vascular dementia did not lead to a reduction in cognitive impairment and clinical improvement in patients with vascular dementia.

[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA].

Purpose - studying of clinical efficiensy of the combined therapy (Amlodipin with Valsartan and fibrates) in hypertensive patients with dyslipidemia. Were studied 58 patients (40-65 years old) with hypertension (the level of arterial pressure was ≥140/90 and ≤180/110mm.Hg.RR). The patients have been divided into 3 groups: Group 1( n=18, middle age 55,8±5,9) were given Amlodipin 10 mg., Fenofibrates 200mg. (Lipantil); Group 2 (n=20, middle age 58,0±4,9) were given Exforge (Amlodipin 5mg./Valsartan 160mg.) and Lipantil 200mg.; Group3 (n=20, middle age 57,0±6,9) were given Exforge. Research duration- 4 months. Was done collection of anamnesis, calculation of BMI, Heart rate, Blood pressure. Before and after observation were investigated: lipid range, Total Cholesterol, Triglycerides, High Density Lipoproteins, Low Density Lipoproteins by using W.Friedwald's formula. After 4 month in group 3 was found significantly reduce of Blood Pressure, systolic- 26,6%, (р<0,001), and diastolic - 18,0%; Significantly improve Lipid range. Were decreased the levels of Total Cholesterol -14,5%, Triglycerides-15,9%, Low Density Lipoproteins -20,2%. The combined therapy by Exforge and fibrates provides effective decrease in levels of blood pressure and improvement in lipid range in hypertensive patients with dyslipidemia.

[Influence of the soybean flavonoid supplement on the synthesis of nitric oxide (NO) in the patients with atherosclerosis].

66 patients of 40-77 age group with atherosclerosis were studied. The observation period made up 4 weeks. The patients were divided into two groups. Group I- experimental group (50 patients) and group II-control group (16 patients) The patients of both groups were given standard therapy, but the patients of group I were additionally given 200mg soybean flavonoid supplement (daily dose 100mg. in capsules two times a day after meals). Clinical observation showed that the patients had no adverse reactions due to intake of the natural food supplement. Compared to the control patients better dynamics of clinical signs was observed in experimental group: reduction of chest pain intensity, arrhythmia and breathlessness, increase of tolerance to physical load, manifested of normalisation arterial hypertension and reduction of heart rate. Biochemical analysis showed an antiatherogenic and hypolipidemic effect of the soybean flavonoid supplement. Statistically reliable increase of NO; reduction of general peripherial vascular resistance and improvement of systolic function. Therefore it can be concluded that given biologically active supplement can be used in the treatment of atherosclerosis as an effective therapeutic tool.